University of Maryland Ebola Essential Role in The Development of Means HW I took a quick look at your report. You may want to resubmit a revised report. Y

University of Maryland Ebola Essential Role in The Development of Means HW I took a quick look at your report. You may want to resubmit a revised report. You may submit a revised report as long as your final version is submitted no later than the due date.

Some reminders:

What to Include in Your Report

Part 6. Include a glossary defining the medical and scientific terms that may not be familiar to a student taking this course. These must be written as complete sentences in your own words and the sources of the definitions cited. (5 points)

Part 7. (7 points possible): Include in-text citations and an evaluative annotated bibliography reference page using APA style; be consistent throughout your report. For instructions see the below section Preparing an Evaluative Annotated Bibliography. Points earned are for complete and accurate citations (6 points) and clear evaluative annotations (2 points).

Required, Acceptable & Unacceptable Sources All cited sources must be available online or through UMGC library databases At least four cited sources of information are required. You must use at least one scholarly article about a research study on the virus or disease (for example, the research article assigned for Part 4 by the instructor) and at least three other sources, which include at least one online textbook (e.g., the Parker et al. (2016) OpensStax Microbiology textbook used in class); at least one Web site run by a reputable organization, such as the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO); and another reputable source.

Citing Sources APA style in-text and complete reference citations are required. Links showing examples are included in this section of What to Include in Your Report.

Assignment Overview write a 2000-2500 word (approximately 10 to 12 pages double spaced) ; this does not include figures, tables, footnotes, bibliography, and glossary of terms research topic report Running Head: EBOLA ANALYSIS
1
Ebola Analysis
Name
Course
Date
2
EBOLA ANALYSIS
Ebola
Abstract
Ebola is one of the known conditions that have a negative health impact to the affected
patients. Based on the rate of fatality linked with this condition, it is so far one of the conditions
that bring about the adverse effect to the general community in the areas where it may occur
(Timothy et al., 2019). The treatment approach used to the management of this condition is
relatively complex, and this results in a significant impact in the healthcare sector. However,
although there is a significant health impact that is linked with the virus that leads towards Ebola,
there is a notable benefit that is connected with the virus. The system is responsible for the
development of an antibody that helps in fighting off an infection that may affect the body in a
subsequent time. For the patients suffering from Ebola, the system is responsible for the
production of antibodies that are useful in the reduction of the complexity of the condition. The
antibodies that are produced by the body of the survivors have a significant role in the overall
decrease in the rate of infection. According to studies, the isolation of antibodies from the blood
of the survivors has shown the ability to reduce the effects that may be linked with the additional
condition. Although the impact of the antibodies obtained from the survivors has so far been
tested on other primates other than human beings, studies are underway to evaluate whether the
antibodies can be administered to human samples to help in the reduction of the rate of infection
of Ebola in case there is an outbreak.
Background
Based on the rate at which the virus that brings about Ebola spreads, it is essential to note
that there are means that can be useful in the reduction of the rate at which the virus spreads. The
3
EBOLA ANALYSIS
virus that is responsible for Ebola may spread in many ways to the affected person (Rojas et al.,
2020). Physical contact with the affected person as well as the connection with the fluids that
may come from the affected person is one of the ways that are well known to the spread of the
virus. After the virus enters the body, it brings about negative health outcome to the body of the
affected. After the virus enters the body, it may showcase with some symptoms such as muscle
pain, fever, headache as well as chills in the affected patient. In the later dates as the condition
advances in the system of the affected person, it is likely to showcase other significant symptoms
such as internal bleeding. Through the internal bleeding that one is likely to show as a result of
the spread of the virus in the body, they are likely to vomit and cough blood. Although the virus
is expected to affect human beings more, there are other animals that are likely to suffer from
this condition more. For the other animals apart from human beings, the rate of infection of the
condition is expected to have a negative impact since the mode of treatment that can be used is
unknown. Mice are the animals that are likely to suffer more in the cause of an outbreak of this
condition. The main aim of this study is to analyze the possible effects that the condition is likely
to bring about to other nonhuman primates. The foundation of the study is based on the fact that
the symptoms that the condition shows in humans, as well as the effects that it brings about, are
well known. Based on this, it will be necessary to evaluate the rate at which it enters the body as
well as the effects that it is likely to bring about to the nonhuman samples.
On the basis of the main aim of the study, it will be essential to analyze the rate at which
the virus may spread in the nonhuman samples and also ensure that an appropriate condition is
kept to ensure that the study is not affected. Since researchers have already started analysis on
the basis of the assessment of the benefits that the use of antibodies may have, it will be
necessary for the evaluation of the effects that the virus is likely to have on mice. The virus will
4
EBOLA ANALYSIS
be removed from the human survivors in order to assist in the completion of the assessment. To
get an antibody, the study will involve the acquisition of the already acquired antibodies from the
well-known laboratories that have previously collected antibodies regarding this condition.
Nonhuman samples of mice will be used to evaluate the rate at which the virus is likely to have a
health impact as well as the measures that may be needed to reduce the rate at which it may
spread in the selected sample. Several variables will be considered in this study. The dependent
variable is the nonhuman sample which will be subjected to the virus as well as antibodies from
a survivor from this condition. The independent variables will be the Ebola virus that will be
evaluated to decide whether it has a significant influence on the patient. On the other hand, the
antibodies from survivors with this condition will act as a control variable that will be necessary
for the assessment of the reduction of the infection that one is likely to gain from this condition.
Hypothesis to use
H0: Non-human samples are not likely to survive virus attack involving Ebola after the injection
with antibodies
H1: nonhuman primates are able to overcome the Ebola virus after being injected with
antibodies.
Experimental design
Mice
Subjecting the
subject to
Sofosbuvir
sample
Subjecting to
virus
5
EBOLA ANALYSIS
The process mentioned above will involve the involvement of all variables that will lead to
appropriate decision making. The sofosbuvir will be the control variable in the study that will be
necessary for evaluating the effects that the virus may have on the mice. Based on the
contribution of the control variable to this, it will have a positive impact, thus a positive control
group.
Number of mice
Change
Percentage change
9
60%
affected
Before using the
15
sofosbuvir
After the sofosbuvir is
6
used
Based on the results of this study, one needs to note that the use of the sofosbuvir is likely
to bring about a significant reduction in the rate at which the viral infection is expected to have
an effect. Additionally, the results show that having an antiretroviral is likely to reduce the
possible negative challenges linked with a viral infection are likely to be effectively managed
and controlled.
It is the role of antibodies to ensure that they can neutralize the virus that is likely to
affect the system. On the basis of the effects that are linked with a specific condition, one needs
to note that the knowledge in the particular health condition may play a critical role in the
6
EBOLA ANALYSIS
creation of an appropriate method that may lead towards the management of the involved disease
(Kangbai et al., 2019). The sofosbuvir was able to reduce the complexity of the virus, and this
translates to the mechanism that is used by the antibodies from the human survivors in the
management of the infection. Since the virus affects the body and causes it to create antibodies,
the antibodies are equipped with the adequate mechanism as well as information regarding the
virus and this assists in the management of the virus.
7
EBOLA ANALYSIS
References
Kangbai, J. B., Heumann, C., Hoelscher, M., Sahr, F., & Froeschl, G. (2019). Sociodemographic
and Clinical Determinants of In-Facility Case Fatality Rate for 938 Ebola Patients
Treated at Sierra Leone Ebola Treatment Center. Available at SSRN 3402012.
Rojas, M., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Ansari, A.
A., … & Anaya, J. M. (2020). Ebola virus disease: An emerging and re-emerging viral
threat. Journal of autoimmunity, 106, 102375.
Timothy, J. W., Hall, Y., Akoi-Boré, J., Diallo, B., Tipton, T. R., Bower, H., … & Carroll, M. W.
(2019). Early transmission and case fatality of Ebola virus at the index site of the 2013–
16 west African Ebola outbreak: a cross-sectional seroprevalence survey. The Lancet
Infectious Diseases, 19(4), 429-438.

Purchase answer to see full
attachment